Altimmune Shares Drop After Company Announces $75 Million Registered Direct Offering
Altimmune Inc. disclosed a $75 million registered direct offering of common stock to a new institutional investor, a move that coincided with a roughly 6.2% decline in premarket trading. Proceeds are earmarked to support preparation for a Phase 3 trial of pemvidutide in metabolic dysfunction-associated steatohepatitis (MASH) and for general corpora…